Entera Bio Valuation

Is 5DT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 5DT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 5DT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 5DT's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 5DT?

Key metric: As 5DT barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 5DT. This is calculated by dividing 5DT's market cap by their current book value.
What is 5DT's PB Ratio?
PB Ratio9.5x
BookUS$6.45m
Market CapUS$58.56m

Price to Book Ratio vs Peers

How does 5DT's PB Ratio compare to its peers?

The above table shows the PB ratio for 5DT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average13.1x
VSC 4SC
47.4xn/a€48.2m
MDG1 Medigene
1x11.0%€22.5m
HPHA Heidelberg Pharma
3x-33.0%€102.1m
2INV 2invest
1xn/a€62.7m
5DT Entera Bio
9.5x-100.3%€58.6m

Price-To-Book vs Peers: 5DT is good value based on its Price-To-Book Ratio (9.5x) compared to the peer average (13.1x).


Price to Book Ratio vs Industry

How does 5DT's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
5DT 9.5xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 5DT is expensive based on its Price-To-Book Ratio (9.5x) compared to the European Biotechs industry average (2.4x).


Price to Book Ratio vs Fair Ratio

What is 5DT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

5DT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio9.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 5DT's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies